SOURCE: Easton Pharmaceuticals, Inc.
TORONTO, ON--(Marketwired - Mar 31, 2014) - Easton Pharmaceuticals Inc. (OTC: EAPH) -- announces it has appointed Carla Pepe as its new CEO and President, replacing John Adams who will assume the position of CFO. The company also announces the addition of Dr. Lilla Albert PhD to the advisory board, chief marketing officer, and Mr. Tim Zorn, current CEO of HempLifeToday.com (OTC: GLCO) to advisory board.
Mrs. Pepe's business experience has already proven to be a positive impact to the company as her efforts through the introduction of various consultants has directed it to enter into the medical marijuana industry and other acquisitions. Mrs. Pepe and other principles have recently introduced the company to other suggested consultants and specialists in not only the medical marijuana industry, but experts in transdermal delivery technology. Through the assistance and introductions of Mrs. Pepe, the company is in negotiations to hopefully enter in an employment agreement with a respected specialist who if he agrees to work on behalf of the company, will present a proposal regarding other medical cannabis opportunities within the state of Colorado (separate from a previously signed letter of intent), access to others and evaluate all other options involving both the U.S. and Canadian medical cannabis industry. The company is also pleased to announce the appointment of Dr. Lilla Albert PhD. to the advisory board and will assume the role of chief marketing and technology officer. In addition Easton announces the appointment of Mr. Tim Zorn, current CEO of HempLifeToday.com to the advisory board to assist in coordinating the development of new Hemp based and other products which are to be marketed and sold on HempLifeToday.com's website which is soon to be expanded and improved.
Easton Pharmaceuticals Inc, a specialty pharmaceutical company that owns, designs, develops, and markets an array of topically-delivered drugs and therapeutic / cosmetic healthcare products, recently partnered with HempLifeToday in a development, marketing and distribution program as well as both companies jointly developing a new line of innovative Hemp and non hemp based products such as Easton Pharmaceuticals' Skin Reno HA, a new Anti Aging / Moisturizer Product. HempLifeToday.com will be assisting Easton with not only the marketing and sale of products, but also with any regulatory submissions or filings within the United States, if required. Easton Pharmaceuticals is currently in the process of applying for approval to have Viorra marketed and sold in Mexico through its partnership with BMV Medica SA who are close to sourcing an FDA approved manufacturing partner and distributor in Mexico who can manufacture Viorra and possibly other products for the Unites States, Canadian and International markets. In addition, an application is to be submitted to health Canada to have its products approved and sold in the country of Canada. Most of Easton's products maintain ingredients that are classified by the FDA as generally regarded as safe (GRAS).
Tim Zorn, CEO of HempLifeToday.com stated, "I am excited to be on the advisory committee of Easton Pharmaceuticals and provide my assistance going forward. The previously announced joint venture allows both of our companies to work closely together to develop and distribute an array of exciting new Hemp, non Hemp and possibly Medical Marijuana products. HempLifeToday has the Marketplace to do so."
Carla Pepe, new CEO and director of Easton Pharmaceuticals, commented, "In my capacity as new CEO, I am looking forward to assisting the company in any way I can and will do my outmost to bring the company's business and initiatives forward." Easton Pharmaceuticals hopes to soon be announcing some very positive developments within various segments of our business as well as announce some new skilled people in different roles."
In other news, due to the fact Easton was not able to have its new website updated and brought live in sufficient time to be reviewed by the Total Health show slated for April 4 to 6 in Toronto, Canada, the company has had to unfortunately cancel its participation in the show. The total health show maintains requirements that all ingredients be stated on a company's website for products being submitted for the health show. Unfortunately, the company's new updated website was only brought live in the last few days which did not provide enough time to prepare or to have its application reviewed.
This news release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when used in the preceding of discussion, the words "anticipate," "pleased," "plan," "confident that," "believe," "expect," "possible" or "intent to" and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. There are no guarantees or assurances that any proposals, initiatives or negotiations will result in a deal acceptable to the company. Any investment made into Easton Pharmaceuticals would be classified as speculative. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company's financial reports and filings.